Efficacy and safety of fondaparinux in preventing venous thromboembolism in Chinese cancer patients: a single-arm, multicenter, retrospective study.
adverse event
bleeding event
cancer
fondaparinux
venous thromboembolism
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2023
2023
Historique:
received:
14
02
2023
accepted:
02
05
2023
medline:
14
6
2023
pubmed:
14
6
2023
entrez:
14
6
2023
Statut:
epublish
Résumé
Fondaparinux is a synthetic anticoagulant for the prevention of venous thromboembolism (VTE), and its administration in Chinese cancer patients is rarely reported. This study aimed to assess the efficacy and safety of fondaparinux in preventing VTE in Chinese cancer patients. A total of 224 cancer patients who received fondaparinux treatment were reviewed in this single-arm, multicenter, retrospective study. Meanwhile, VTE, bleeding, death, and adverse events of those patients in the hospital and at 1 month after treatment (M1) were retrieved, respectively. The in-hospital VTE rate was 0.45% and there was no (0.00%) VTE occurrence at M1. The in-hospital bleeding rate was 2.68%, among which the major bleeding rate was 2.23% and the minor bleeding rate was 0.45%. Moreover, the bleeding rate at M1 was 0.90%, among which both the major and minor bleeding rates were 0.45%. The in-hospital death rate was 0.45% and the death rate at M1 was 0.90%. Furthermore, the total rate of adverse events was 14.73%, including nausea and vomiting (3.13%), gastrointestinal reactions (2.23%), and reduced white blood cells (1.34%). Fondaparinux could effectively prevent VTE with low bleeding risk and acceptable tolerance in cancer patients.
Identifiants
pubmed: 37313468
doi: 10.3389/fonc.2023.1165437
pmc: PMC10258345
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1165437Informations de copyright
Copyright © 2023 Wang, Su, Xie, Li, Pan, Xu, Chen and Cheng.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Thromb Thrombolysis. 2020 Aug;50(2):267-277
pubmed: 32583306
Prog Mol Biol Transl Sci. 2019;163:41-53
pubmed: 31030756
PLoS One. 2018 Nov 9;13(11):e0207410
pubmed: 30412622
J Cardiol. 2022 Jan;79(1):79-89
pubmed: 34518074
Expert Rev Pharmacoecon Outcomes Res. 2007 Jun;7(3):227-37
pubmed: 20528310
Drug Des Devel Ther. 2016 Jun 23;10:2041-6
pubmed: 27382257
Blood. 2020 Sep 17;136(12):1433-1441
pubmed: 32396939
Best Pract Res Clin Haematol. 2022 Mar;35(1):101354
pubmed: 36030074
Arch Intern Med. 2006 Feb 27;166(4):458-64
pubmed: 16505267
Int J Surg. 2017 Jun;42:203-208
pubmed: 28392450
Drugs. 2010 Dec 14;70 Suppl 2:3-10
pubmed: 21162604
Eur J Med Chem. 2022 Apr 15;234:114256
pubmed: 35279609
Int J Cardiol. 2019 Oct 1;292:198-204
pubmed: 31239211
Best Pract Res Clin Haematol. 2009 Mar;22(1):9-23
pubmed: 19285269
Expert Rev Hematol. 2020 Feb;13(2):155-173
pubmed: 31958251
J Thromb Haemost. 2020 Jan;18(1):180-190
pubmed: 31549765
Support Care Cancer. 2022 Apr;30(4):2919-2931
pubmed: 34617159
Thromb Res. 2020 Jul;191 Suppl 1:S79-S84
pubmed: 32736784
Drugs Today (Barc). 2002 Mar;38(3):185-94
pubmed: 12532174
Am J Health Syst Pharm. 2001 Nov 1;58 Suppl 2:S14-7
pubmed: 11715834
Arch Intern Med. 2004 Jan 26;164(2):190-4
pubmed: 14744843
Am J Health Syst Pharm. 2014 Apr 1;71(7):562-9
pubmed: 24644116
N Engl J Med. 2001 Nov 1;345(18):1305-10
pubmed: 11794149
Oncologist. 2021 Jan;26(1):e17-e23
pubmed: 33275323
Lancet. 2021 Jul 3;398(10294):64-77
pubmed: 33984268
J Blood Med. 2021 Feb 11;12:69-75
pubmed: 33603528
Drugs. 2020 Sep;80(13):1293-1308
pubmed: 32691292